

# Evaluation of Agnostic RNA Sequencing for Biothreat & Emerging Infectious Disease Detection

Signature Science, LLC: Kathleen Q. Schulte, Elizabeth A. Scheuermann, Nicolette C. Keplinger, Matthew B. Scholz, Leah W. Allen, Amanda N. Scholes, Taylor A. Wolt, Viviana M. June, Cole J. Schulte, Krista L. Ternus, F. Curtis Hewitt, and Anthony D. Kappell\*

## INTRODUCTION

### Background

- The identification of RNA viruses from mixed samples, or from samples of individuals known to be ill, but without official diagnosis is a vital step for diagnosis and treatment for patients.
- In recent years, there have been multiple outbreaks of RNA viruses.
  - SARS-CoV2, Chikungunya virus, Zika virus, and RSV.
- The detection of RNA viruses by standard testing (antibody testing, RT-qPCR, etc.) are complicated by the rapid mutation rates of RNA viruses
- The need for reverse transcription to DNA for amplification based tests, and the need for cell culture to propagate viral stocks.
- This protocol provides a sequencing methodology using optimized
- Oxford Nanopore protocols coupled with an analysis pathway (SigSciDx) for rapid, agnostic, low cost diagnosis of RNA viruses from an un-amplified and uncultured sample.
- Accuracy of SigSciDx was assessed against multiple contrived samples (Influenza A, RSV, and Human Coronavirus 229E) in viral transport media and in human plasma. We demonstrate a 62.9% clinical sensitivity and 100% specificity rate for these samples.

### Study

- We have established a 6 clinical sample multiplex (8 total with controls) library preparation workflow for the untargeted, unbiased sequencing of RNA viruses from Viral Transport Media (VTM) and Human Plasma
- This study evaluated the final library preparation workflow using contrived clinical samples and patient remnant samples.



Ebola Virus


## REFERENCES

- N. Sapoval, et al. (2021) Hidden genomic diversity of SARS-CoV-2: implications for qRT-PCR diagnostics and transmission, Genome Res.
- Y. Xu, et al. (2018) Detection of Viral Pathogens With Multiplex Nanopore MinION Sequencing: Be Careful With Cross-Talk, Front. Microbiol. 9. (And Citations Within)
- F.C. Hewitt, et al. (2017) Toward Rapid Sequenced-Based Detection and Characterization of Causative Agents of Bacteremia, BioRxiv. 162735.
- H.P. McLaughlin, et al. (2020) Rapid Nanopore Whole-Genome Sequencing for Anthrax Emergency Preparedness, Emerg. Infect. Dis. 26 (2020) 358–361.
- J.A. Russell, et al. (2018) Unbiased Strain-Typing of Arbovirus Directly from Mosquitoes Using Nanopore Sequencing: A Field-forward Biosurveillance Protocol, Sci. Rep. 8. 5417.
- M.R. Lindberg, et al. (2016) A Comparison and Integration of MiSeq and MinION Platforms for Sequencing Single Source and Mixed Mitochondrial Genomes, PLOS ONE. 11. e0167600.
- CDCgov/SARS-CoV-2\_Sequencing, Centers for Disease Control and Prevention, 2021. [https://github.com/CDCgov/SARS-CoV-2\\_Sequencing](https://github.com/CDCgov/SARS-CoV-2_Sequencing)
- S.T. Calus (2018). NanoAmpli-Seq: a workflow for amplicon sequencing for mixed microbial communities on the nanopore sequencing platform. Gigascience, 7(12), gjy140. [Workflow contains adapted figure]
- A. Balaji et al. (2022). SeqScreen: accurate and sensitive functional screening of pathogenic sequences via ensemble learning. Genome Biology, 23(1), 133.
- A. Balaji et al. (2023). SeqScreen-Nano: a computational platform for rapid, in-field characterization of previously unseen pathogens. bioRxiv, 2023-02.

## MATERIALS AND METHODS

**Contrived Samples:** Virus free pooled remnant VTM or plasma spiked with relevant viruses  
**Remnant Samples:** Remnant VTM samples for respiratory viruses  
**Internal Control:** MS2 Phage added to each sample at extraction  
**Process Control:** Green-fluorescent protein mRNA

### Library Preparation Workflow



### SigSciDx Bioinformatic Pipeline



SeqScreen's Taxonomical Inference Module <sup>8,9</sup>												
Barcode	Species	Taxonomy ID	Source Database	Assembly Level	No of Reads	Coverage	Depth	Coverage-2nd	Depth-2nd	ANI	Combined	Presence/Absence
barcode04	Human coronavirus 229E	11137	NaN	Complete Genome	1315	0.987297	37.635671	0.987151	37.615021	0.929547	95.17	Present
barcode04	Respiratory syncytial virus	12814	NaN	Complete Genome	516	0.966493	32.283340	0.966493	32.283340	0.976022	95.48	Present
barcode04	Escherichia phage MS2	12022	NaN	Complete Genome	15437	0.959933	1865.009048	0.959933	1864.934910	0.997351	95.87	Present

## RESULTS

### Performance Characteristics for the Agnostic RNA Sequencing Assay

Performance Metric	Method	Result																					
Limit of detection (LoD)	Qualitative detection of RNA virus dilution replicates by probit analysis	<b>Pathogen</b> → <b>LoD (Estimated PFU<sup>1</sup>)</b> Influenza A Virus → 26,915 TCID <sub>50</sub> /mL (18,840 PFU/mL) Human Respiratory Syncytial Virus → 214 TCID <sub>50</sub> /mL (150 PFU/mL) Human Coronavirus 229E → 1 TCID <sub>50</sub> /mL (1 PFU/mL) Zika Virus → 550 TCID <sub>50</sub> /mL (385 PFU/mL) Hepatitis A Virus → 1318 TCID <sub>50</sub> /mL (923 PFU/mL) Yellow Fever Virus → 68 TCID <sub>50</sub> /mL (47 PFU/mL) Chikungunya Virus → 115 TCID <sub>50</sub> /mL (80 PFU/mL)																					
Precision	Qualitative detection over 2 to 7 contrived sample runs of each organism (inter-assay) <sup>2</sup> Qualitative detection of duplicate contrived samples on the same run (intra-assay) <sup>2</sup> Qualitative detection over 21 remnant sample (duplicate or triplicate) runs (inter-assay)	100% concordance 100% concordance 100% concordance																					
Interference	Quantitative read count of viruses with spiked blood (5%, 2%) Quantitative read count of viruses with spiked EDTA (100 mM, 10 mM, 5 mM) Quantitative read count of viruses with spiked bacteria ( <i>Micrococcus luteus</i> or <i>Staphylococcus epidermidis</i> )	Decrease of number of reads by 1.3-Logs to 1.5-Logs mapped to viruses Decrease of number of reads by 0.6-Logs and 0.1-Logs with addition of 100 mM and 10 mM EDTA, respectively No significant changes in number of reads mapped to RNA viruses																					
Accuracy	18 of single-detection remnant sample runs, results comparisons (3 for each organism).	<table><tr><th>Pathogen</th><th>Sensitivity</th><th>Specificity</th></tr><tr><td>Human metapneumovirus</td><td>33.3%<sup>3</sup></td><td>100%</td></tr><tr><td>Parainfluenza IV</td><td>100%</td><td>100%</td></tr><tr><td>SARS-CoV-2</td><td>100%</td><td>100%</td></tr><tr><td>RSV</td><td>100%</td><td>100%</td></tr><tr><td>Influenza A</td><td>100%</td><td>100%</td></tr><tr><td>Enterovirus</td><td>100%</td><td>100%</td></tr></table>	Pathogen	Sensitivity	Specificity	Human metapneumovirus	33.3% <sup>3</sup>	100%	Parainfluenza IV	100%	100%	SARS-CoV-2	100%	100%	RSV	100%	100%	Influenza A	100%	100%	Enterovirus	100%	100%
Pathogen	Sensitivity	Specificity																					
Human metapneumovirus	33.3% <sup>3</sup>	100%																					
Parainfluenza IV	100%	100%																					
SARS-CoV-2	100%	100%																					
RSV	100%	100%																					
Influenza A	100%	100%																					
Enterovirus	100%	100%																					

<sup>1</sup> Estimated PFU calculated by multiplying the TCID<sub>50</sub>/mL by 0.7 • <sup>2</sup>Nearest higher loading to that of the LOD (within 1-Log) • <sup>3</sup>Includes two of the three samples that did not pass internal control QC

## CONCLUSIONS

- Best method identified was REPLI-g assisted Double-stranded cDNA synthesis as input into the Native Barcoding Kit and Ligation Sequencing Kit to generate an 8-sample multiplex library preparation with 6 samples and 2 controls.
- Supports multiplex up to 6 samples with approximately 9 (1-plex) to 11 (6-plex) hours of hands-on sample preparation (no automation).
- Current limit of detection is higher than targeted PCR assays and near that of immuno-based assays.
- Detection limits appear to be associated with genome size and complexity of the genome (e.g. segmentation) of the virus.
- Sensitivity is 100% down to 33% - Discrepancy testing was not performed to confirm remnant sample original result .
- Specificity was at 100%.
- Results are in Preprint: medRxiv 2024.03.26.24304688 and original workflow development: medRxiv 2024.03.26.24304686


## FUTURE DIRECTIONS

- Transitioning to R10 chemistry.
  - Increase in read quality and decrease in error is expected.
  - New R10 Kit is compatible with workflow.
- Reduce time from sample to prepared library.
  - WGA produces excess amounts of DNA, therefore incubation time can be reduced.
  - Reverse-transcription incubation time can be reduced and/or a faster enzyme kit could be used.
- Re-examine the use of the Rapid Barcoding Kit.
  - Will need to revisit barcode cross-talk.
- Reduce overall processing and time for a single-sample library preparation and automate that process (Currently funded).
- Scale the automated single-sample library preparation to be capable of processing multiple samples (6 to 12) for a single sequencing run.

## ACKNOWLEDGEMENTS

This research was funded by Centers for Disease Control and Prevention under award numbers 75D30121C12250 and 75D30122C15359. Additionally, the development of SeqScreen and SeqScreen-Nano utilizing the taxonomical inference module was funded through IARPA Award No. W911NF-17-2-0089. The view and conclusions contained herein are those of the authors and should not be interpreted as official policy or endorsement of the HGS, CDC, ODNI, IARPA, ARO or the US Government.

### High Concentration of EDTA Negatively Impacted Read Count



### High Concentration of Blood Negatively Impacted Read Count

